A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 457 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma November 4, 2022 Today is Random Acts of Kindness Day February 17, 2021 Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... December 12, 2024 Load more HOT NEWS seven Interesting Facts about Malignant tumors Boy Between the sheets Managing Side Effects with South Asian Foods Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic... How to Find a Caregiver When You Have Cancer
